First half characteristics of the API industry: strong corporate performance, profitability continued to improve

Pharmaceutical Network Market Analysis: In the first half of 2020, how did the performance of enterprises in the specialty API industry perform? From the market attention of high characteristics of API enterprises, the overall performance is good, strong corporate performance, the first half of the profitability continued to improve.
, Staili achieved operating income of 722 million yuan in the first half of the year, up 13.56 percent from a year earlier, and net profit attributable to shareholders of listed companies was 140 million yuan, up 50 percent year-on-year.
said in its 2020 mid-year report that its operating income was 1.77 billion yuan, down 4.78 percent year-on-year, and net profit attributable to shareholders of listed companies was 205 million yuan, up 18.2 percent year-on-year.
Huahai Pharmaceuticals achieved operating income of RMB3.306 billion in the first half of the year, up 24.6% YoY, and net profit attributable to shareholders of listed companies was RMB578 million, up 72.77% YoY.
Tianyu shares achieved operating income of RMB1,332 million, up 36.17% YoY, and net profit attributable to shareholders of listed companies was RMB381 million, up 50.07% YoY.
reported first-half operating income of 651 million yuan, up 16.01 percent year-on-year, and net profit of 107 million yuan, up 24.57 percent year-on-year.
Pharmaceuticals achieved operating income of RMB3,992 million in the first half of 2020, up 12.46% YoY, and net profit of RMB429 million, up 52.93% YoY.
Aoxiang Pharmaceuticals recently released its semi-annual report showing that the company achieved revenue of 210 million yuan in the first half of the year, up 62.38 percent year-on-year, and net profit of 52.598 million yuan, up 69.46 percent year-on-year.
Pharmaceuticals achieved operating income of RMB237 million in the first half of 2020, up 21.60% YoY, and net profit attributable to shareholders of listed companies achieved RMB41.7392 million, up 55.71% YoY.
Fuxiang Pharmaceuticals achieved total operating income of 820 million yuan in the first half of 2020, up 37.8% YoY, and net profit of 220 million yuan, up 92% YoY.
The average revenue growth rate of the nine representative API companies reached 24.42%, far exceeding the growth rate of the chemicals and pharmaceutical industry as a whole, and the average net profit growth rate was 53.97%, far higher than that of the chemicals and pharmaceuticals industry as a whole.
industry analysis, the high business climate of the specialty API industry is mainly due to the increase in industry concentration and the continued growth of downstream demand.
is worth noting that the characteristics of API enterprises are moving towards two major trends.
, specialty API companies continue to promote the integration of API-preparations.
from the semi-annual reports of major enterprises, 2020H1, Xianxian Pharmaceuticals, Huahai Pharmaceuticals, Pro Pharmaceuticals, the proportion of preparation income reached 50%, 48% and 9%, respectively.
but in the first half of the year, affected by the outbreak, sales of some preparation varieties declined, with revenues of 6% and 37%, respectively, for cents and prolo pharmaceuticals.
and Huahai Pharmaceuticals benefited from the release of the winning varieties, with preparation revenue increasing by 27%.
industry believes that the "Huahai model" will lead to the characteristics of API-pharmaceutical enterprises continue to promote the integration of API-preparations.
with the normalization of collection, the bargaining power of specialty API enterprises is enhanced, and the initiative to extend downstream is also available.
enterprises that are preemptively laid out in the field of preparations and have significant synergies with the original specialty raw materials are expected to gain opportunities.
, on the other hand, specialty API companies are also transitioning to the CMO/CDMO industry.
2020H1, clearly layout CMO / CDMO business of specialty API companies including Tianyu shares, Novarlor, Pro Pharmaceuticals, Oxiang Pharmaceuticals, Tong and Pharmaceuticals and so on.
with the continued expansion of the global CMO/CDMO market, the industry continues to shift to the domestic, rich technology reserves, strong management capacity of specialty API enterprises will be expected to occupy a larger market share.
Overall, in the short term, with the sustained environmental protection and high pressure, quality standards, the concentration of the API industry will continue to improve, leading enterprises have a competitive advantage;
long term, the demand for specialty API has grown steadily, and the development prospects of the industry are still promising.